ConductScience.org, home

Comparison · NCT02499354-81563b2a

Oral Iron vs IV Iron: Number of Participants With Adverse Events Judged Related or Possibly Related to Treatment.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Oral Iron vs IV Iron: Number of Participants With Adverse Events Judged Related or Possibly Related to Treatment. Trial comparisons, record NCT02499354-81563b2a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02499354-81563b2a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4780.3410.619wilson
Risk in group 20.2340.1360.372wilson
Risk difference, group 1 minus group 20.2440.04960.415newcombe hybrid score
Risk ratio, group 1 over group 22.041.123.72log
Odds ratio, group 1 over group 231.237.3log
Number needed to treat, for one more participant with the outcome on Oral Iron than on IV Iron4.092.4120.2from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Oral Iron
Ferrous Sulfate 325mg (oral) tabs morning and evening~Ferrous sulfate: Oral iron, 325 mg tabs taken morning and evening~In this arm participants also received intravenous normal saline as part of a double blind, double dummy design
2246OG000
Group 2IV Iron
Ferumoxytol intravenous (IV) 1020 mg - 2 vials of 510 mg (IV push, 2-3 mins) each given 2-7 days apart~Ferumoxytol intravenous: IV iron, 2 vials of 510 mg given 2-7 days apart~In this arm participants received oral vitamin C as part of a double blind, double dummy design
1147OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Adverse Events Judged Related or Possibly Related to Treatment.
Description
Patient reported gastrointestinal or constitutional adverse events
Time frame
Up to six weeks
Population

Source ClinicalTrials.gov

Trial

Title
Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)
NCT number
NCT02499354
Phases
PHASE2
Conditions
Restless Legs Syndrome, Iron Deficiency Anemia
Interventions
Ferumoxytol intravenous, Ferrous sulfate
Lead sponsor
Auerbach Hematology Oncology Associates P C
Results first posted
2023-08-15

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02499354-81563b2a